MedTrace Logo

Endothelial Markers and Tadalafil Response

NCT07773103 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-08-20

No results posted yet for this study

Summary

This prospective cohort study will recruit eligible men attending the Urology/Andrology outpatient clinic. Baseline assessment will include demographic and clinical data, cardiovascular risk assessment, erectile-function questionnaires, routine laboratory investigations, brachial artery flow-mediated dilatation, carotid intima-media thickness, and selected circulating endothelial biomarkers including endothelin-1, nitrite/nitrate, high-sensitivity C-reactive protein, soluble vascular cell adhesion molecule-1, and soluble intercellular adhesion molecule-1. All participants will receive tadalafil 5 mg once daily for 12 weeks. Erectile function, adherence, and adverse events will be assessed during follow-up. The primary outcome will be clinical response at 12 weeks, defined as an improvement of at least 4 points in the IIEF-EF domain together with a positive response to the Global Assessment Question.

Conditions

  • Vasculogenic Erectile Dysfunction

Interventions

DRUG

Tadalafil 5mg

All enrolled participants will receive tadalafil 5 mg orally once daily for 12 weeks as part of clinical management.

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Abul-fotouh Ahmed · Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-19
Primary Completion
2028-08-31
Completion
2028-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07773103 on ClinicalTrials.gov